Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 2/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.30 |
| ▸ | CDK2 | P24941 | 2/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215053 | 0.86 | ADORA2A (0.40) | ADORA1CDK1CCNB1CDK2CCNA2 | |
| SCHEMBL11222090 | 0.85 | PDPK1 (0.32) | PDPK1GDAALDH1A1 | |
| Hydrochloric Acid SCHEMBL7735731 | 0.85 | ADORA2A (0.40) | ADORA1CDK1CCNB1CDK2CCNA2 | |
| Barbital SCHEMBL2130349 | 0.85 | LMNA (0.44) | ALDH1A1 | |
| SCHEMBL17060282 | 0.84 | PDPK1 (0.32) | PDPK1GDA | |
| SCHEMBL7490404 | 0.83 | ADORA2A (0.43) | ADORA1CDK1CCNB1CDK2CCNA2 | |
| SCHEMBL4551801 | 0.82 | ADORA2A (0.44) | ADORA1PDPK1CDK1CCNB1CDK2 | |
| SCHEMBL9176115 | 0.82 | GDA (0.32) | PDPK1GDA | |
| SCHEMBL10615800 | 0.81 | CDK1 (0.37) | CDK1CCNB1CDK2CCNA2CCNA1 | |
| SCHEMBL6379581 | 0.81 | HRH2 (0.37) | PDPK1GDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-116492347-A | Compound for activating AMPK and application thereof | 华安医学股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| EP-2427195-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2019-05-01 | — | — | EP | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-8172873-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2012-05-08 | — | — | US | disclosed |
| US-20110251364-A1 | Shape Memory Polymers | NATIONAL SCIENCE FOUNDATION | 2011-10-13 | — | — | US | disclosed |
| US-7935131-B2 | Shape memory polymers | UNIVERSITY OF ROCHESTER (US) | 2011-05-03 | — | — | US | disclosed |
| US-20080177303-A1 | Shape memory polymers | ROCHESTER, UNIVERSITY OF | 2008-07-24 | — | — | US | disclosed |
| WO-2002018582-A9 | 62112, A NOVEL HUMAN DEHYDROGENASE AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2003-04-03 | — | — | WO | disclosed |
| EP-1045927-A1 | MULTIPLEX VGID | ValiGene Corporation (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1015474-A1 | DON-1 GENE AND POLYPEPTIDES AND USES THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| CN-1242373-A | Novel arabinosyladenine derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-01-26 | — | — | CN | disclosed |
| WO-1999036575-A1 | MULTIPLEX VGID | VALIGENE CORPORATION (US) | 1999-07-22 | — | — | WO | disclosed |
| EP-0789577-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 1998-07-22 | — | — | EP | disclosed |
| WO-1998007736-A1 | DON-1 GENE AND POLYPEPTIDES AND USES THEREFOR | MILLENNIUM BIOTHERAPEUTICS, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| EP-0789577-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996040202-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | ADORA1 1262/4885BTK 3989/4885PDPK1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.